Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

SIGA Begins Smallpox Drug Shipments to National Stockpile

by Global Biodefense Staff
March 13, 2013

Smallpox Virus Cluster (CDC)SIGA Technologies this week announced the first of a series of deliveries of its proprietary smallpox antiviral drug, Arestvyr (formerly ST-246) to the Strategic National Stockpile under a contract award by the Biomedical Advanced Research and Development Authority (BARDA).

The delivery reignited controversy over the scope and cost of the drug program, with the New York Times reporting the government is paying more than $200 for each course of treatment. The company defended the pricing as a fair and reasonable return on investment, and a bargain compared to prices charged for some patented drugs such as $20,000 a year for AIDS antiretrovirals or cancer drugs costing more than $100,000 a year.

In 2011, BARDA awarded SIGA the base contract for this initial procurement of 1.7 million treatment courses of ST- 246 (Arestvyr). The five-year award was valued at $433 million, of which approximately $412.5 million is for purchase of the drug. 

The order quantity was based on the amount analysts predicted would be needed to contain a smallpox outbreak in a large city. Asked about the scope of the purchase, SIGA president Dr. Eric A. Rose compared it to an influenza drug. “There are 80 million courses of Tamiflu in the strategic national stockpile,” he said. “Smallpox is just as contagious and has 30 times the mortality. By measures like that, I’d say 2 million is on the low end.”

In the summer of 2012, SIGA was ordered by a Delaware court to share profits from the smallpox drug sales with PharmAthene, Inc. The decision followed 5 years of litigation resulting from a failed merger agreement between the companies.

The court entitled PharmAthene to 50% of the net profits over 10 years from all sales of SIGA Technologies’ novel smallpox antiviral. The profit sharing kicks in once SIGA receives the first $40 million in net profits from sales of ST-246.

Read the New York Times article: Wary of Attack With Smallpox, U.S. Buys Up a Costly Drug.

Tags: AntiviralsASPRBARDABioterrorismHHSPoxvirusesRicinSmallpoxStrategic National Stockpile

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC